Medicine to reduce heart scarring in non-obstructive cardiomyopathy
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new medicine, henagliflozin, to see if it can reduce scarring (fibrosis) in the heart muscle of people with non-obstructive hypertrophic cardiomyopathy. The goal is to improve heart health and slow down disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of non-obstructive hypertrophic cardiomyopathy, meaning the heart muscle is thickened but not blocking blood flow out of the heart.
- You must be willing to undergo special heart imaging tests (like a PET or MRI) to check for scarring.
- Your baseline heart scan must show some scarring (fibrosis) in the heart muscle.
- Your heart symptoms should be mild to moderate, not severe (NYHA class I-III).
- You must not have other major heart conditions, like significant valve disease or severe coronary artery disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called dapagliflozin (usually used for diabetes) can reduce heart tissue changes in people with persistent atrial fibrillation. It is given along with the standard ablation procedure, aiming to improve the heart's electrical health and potentially make the procedure more effective.
This trial uses a special CT scan to create a 3D model of your heart's blood flow. It aims to see if this model can help doctors better predict how well treatments work for people with a thick heart muscle that blocks blood flow.
This study aims to find and treat rare types of heart muscle disease early. If you have heart failure but no known heart disease, researchers will use MRI and other tests to see if a rare cause is behind your symptoms and then offer targeted treatment.
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This study tests whether a diabetes medicine called henagliflozin can reduce liver scarring in people who have both fatty liver disease (MASLD) and type 2 diabetes. If you qualify, you may receive the study drug and help researchers learn if it can improve liver health.
Hear when a new HCM - Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.